HIV Incidence Among Repeat HIV Testers at a County Hospital, San Francisco, California, U.S.A.

Objectives: To estimate HIV incidence, characterize correlates of HIV seroconversion, and monitor temporal trends in HIV transmission among patients repeatedly tested for HIV by a county hospital in San Francisco. Design: Retrospective longitudinal study. Methods: HIV incidence was retrospectively calculated among persons voluntarily tested for HIV antibody more than once at San Francisco’s county hospital or one of its affiliated satellite community clinics between 1993 and 1999. Linkage of HIV test results in computerized databases identified “seroconverters” as individuals who had a negative antibody test followed by a positive test. The interval between tests was used as the person‐time at risk. Cox proportional hazards analysis identified correlates of HIV seroconversion. Results: A total of 84 HIV seroconversions were identified among 2893 eligible patients repeatedly tested for HIV antibody over a cumulative 5860 person‐years (PYs) (incidence of 1.4 per 100 PYs, 95% confidence interval [CI]: 1.2‐1.7). The majority of seroconversions (71 [84.5%]) were among injection drug users (IDUs) (incidence of 2.0 per 100 PYs, CI: 1.6‐2.4). HIV incidence was highest among men who have sex with men (MSM) who were also IDUs (incidence of 3.8 per 100 PYs, CI: 2.7‐5.1) and lowest among non‐IDUs, heterosexual men, and non‐IDU women (incidence of 0.3 per 100 PYs, CI: 0.1‐0.6). In multivariate analysis, correlates of HIV seroconversion were age 25 to 29 years (hazard ratio [HR] = 3.9, CI: 2.4‐6.3), MSM (HR = 2.9, CI: 1.9‐4.4), and IDU (HR = 3.2, CI: 1.8‐5.8). Overall, no temporal trend in annual HIV incidence was noted during the study period; however, HIV incidence among MSM IDUs increased from 2.9 per 100 PYs in 1996 to 4.7 per 100 PYs in 1998. Conclusions: The rate of seroconversion in this hospital and affiliated clinic population is unexpectedly high. Moreover, HIV transmission among IDU patients has not decreased over the last several years. The San Francisco county hospital provides a high‐risk sentinel population to monitor emerging trends in HIV transmission, especially among IDUs, and presents multiple opportunities for prevention interventions, because these patients are being seen repeatedly by clinicians.

[1]  P. Bacchetti,et al.  Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis , 2001, The Lancet.

[2]  M. Katz,et al.  Low estimates of HIV seroconversions among clients of a drug treatment clinic in San Francisco, 1995 to 1998. , 2000 .

[3]  D. Vlahov,et al.  Correlates of HIV infection among young adult short-term injection drug users , 2000, AIDS.

[4]  D. D. Des Jarlais,et al.  HIV incidence among injection drug users in New York City, 1992-1997: evidence for a declining epidemic. , 2000, American journal of public health.

[5]  J. Dilley,et al.  Detection of early HIV infection and estimation of incidence using a sensitive/less-sensitive enzyme immunoassay testing strategy at anonymous counseling and testing sites in San Francisco. , 1999, Journal of acquired immune deficiency syndromes.

[6]  N. Galai,et al.  HIV incidence among repeat HIV testers with sexually transmitted diseases in Italy. STD Surveillance Working Group. , 1999, AIDS.

[7]  J. Parry,et al.  Incidence of HIV infection in homosexual men attending a sexually transmitted disease clinic in London measured by a novel unlinked anonymous method. , 1999, AIDS.

[8]  G. Satten,et al.  HIV seroincidence and risk factors among patients repeatedly tested for HIV attending sexually transmitted disease clinics in the United States, 1991 to 1996. STD Clinic HIV Seroincidence Study Group. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[9]  G A Satten,et al.  New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. , 1998, JAMA.

[10]  D. Hartel,et al.  Methadone treatment protects against HIV infection: two decades of experience in the Bronx, New York City. , 1998, Public health reports.

[11]  R A Coutinho,et al.  Young and recent-onset injecting drug users are at higher risk for HIV. , 1997, Addiction.

[12]  M. Schechter,et al.  Determinants of HIV seroconversion in drug users during a period of rising prevalence in Vancouver , 1997 .

[13]  D. Vlahov,et al.  Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. , 1996, American journal of public health.

[14]  T. Peterman,et al.  Decreasing prevalence hides a high HIV incidence: Miami , 1995, AIDS.

[15]  J. Kaewkungwal,et al.  HIV‐1 incidence determined retrospectively among drug users in Bangkok, Thailand , 1994, AIDS.

[16]  J. Karon,et al.  High HIV‐1 incidence in young women masked by stable overall seroprevalence among childbearing women in Kinshasa, Zaïre: estimating incidence from serial seroprevalence data , 1994, AIDS.

[17]  J. Schmitz,et al.  Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency. , 1998, American journal of public health.